Moximed will leverage $91m in Series D funding to continue building commercial infrastructure and increase patient access to its pioneering MISHA Knee System.
Following its receipt of US Food and Drug Administration De Novo approval in April 2023, “The MISHA Knee System represents a completely new category of implantable shock absorbers for people who are impacted by medial knee OA [osteoarthritis] and are not